Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration ... Seeking Alpha (click to enlarge) Rituxan (rituximab), MabThera in Europe, is a monoclonal antibody against B-lymphocytes CD20 surface protein used to treat lymphomas, leukemias, transplant rejection and rheumatoid arthritis. Novartis' Sandoz generics division is on ... |
